We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Sequenom Sells Bioscience Business to Agena
News

Sequenom Sells Bioscience Business to Agena

Sequenom Sells Bioscience Business to Agena
News

Sequenom Sells Bioscience Business to Agena

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Sequenom Sells Bioscience Business to Agena"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The terms of the agreement provide for a purchase price of $31.8 million, subject to certain adjustments, and Sequenom may also receive up to $4 million in contingent consideration upon the achievement of certain regulatory and sales milestones. Agena Bioscience also assumed certain liabilities related to the Bioscience business, which does not include any portion of Sequenom's bank debt or convertible notes outstanding. The facility lease for its Bioscience location in San Diego was also assumed by Agena Bioscience. All of the current Bioscience employees will be offered employment by Agena Bioscience. 

"We are pleased to sell the business to Agena Bioscience and Telegraph Hill Partners as they plan to invest in the growth of the Bioscience business to achieve its full potential. This sale strengthens our balance sheet, and will enable us to focus exclusively on our Sequenom Laboratories business as we work toward achieving profitability," said Harry F. Hixson, Jr., Chairman and CEO of Sequenom. 

The acquired business will continue to manufacture and sell the MassARRAY® System, a proprietary mass spectrometry-based genetic analysis instrument and associated products and services that provide research and clinical investigators with economical high multiplexing, high volume results, and precise quantification in a well-established platform technology. 

Advertisement